Brain mechanisms underlying the hunger-inducing effect of erythromycin

Brain mechanisms underlying the effect of the motilin receptor agonist erythromycin on hunger in normal weight subjects

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-004411-53-BE

Enrollment

Registered

2014-02-04

Start date

2014-05-15

Completion date

Unknown

Last updated

2021-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The effect of erythromycin administration on hunger and brain responses will be tested in healthy volunteers

Interventions

Trade Name: Erythrocine Pharmaceutical Form: Powder and solution for solution for injection INN or Proposed INN: ERYTHROMYCIN LACTOBIONATE CAS Number: 3847-29-8 Concentration unit: mg/ml milligram(s)/

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Female = 1 Age > 18 and =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Alcohol consumption > 7 drinks / week Major depression and chronic health conditions except controlled hypertension

Design outcomes

Primary

Measure	Time frame
Main Objective: Replicate the established effect of intravenous erythromycin infusion on hunger, and figure out the brain and/or hormonal mechanisms underlying the effect.;Secondary Objective: NA;Primary end point(s): Brain responses to intravenous administration of 40 mg of erythromycin versus placebo in regions involved in homeostatic and hedonic control of food intake;Timepoint(s) of evaluation of this end point: 60 min after the start of the infusion	—

Measure

Time frame

Main Objective: Replicate the established effect of intravenous erythromycin infusion on hunger, and figure out the brain and/or hormonal mechanisms underlying the effect.;Secondary Objective: NA;Primary end point(s): Brain responses to intravenous administration of 40 mg of erythromycin versus placebo in regions involved in homeostatic and hedonic control of food intake;Timepoint(s) of evaluation of this end point: 60 min after the start of the infusion

—

Secondary

Measure	Time frame
Secondary end point(s): Amount of intake of a chocolate milkshake in response to intravenous administration of 40 mg of erythromycin versus placebo;Timepoint(s) of evaluation of this end point: The time that subjects want to stop drinking the milkshake	—

Countries

Belgium

Contacts

Public ContactDongxing Zhao

University of Leuven

dongxing.zhao@med.kuleuven.be00321637 75 45

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026